|
Clinical characteristic
|
NMDAR
|
pa
|
CASPR2
|
pa
|
GAD65
| |
|---|
|
+ n = 21
|
− n = 42
|
+ n = 14
|
− n = 28
|
+ n = 9
|
− n = 18
|
pa
|
|---|
|
Hallucinations, n (%)
|
3 (14.3)
|
1 (2.4)
|
0.10
|
0 (0)
|
3 (10.7)
|
0.54
| | | |
|
Delusions, n (%)
|
2 (9.5)
|
7 (16.7)
|
0.71
|
2 (14.3)
|
3 (10.7)
|
1.00
| | | |
|
Lowered moodb, n (%)
|
10 (55.6)
|
16 (39.0)
|
0.24i
|
8 (61.5)
|
15 (60.0)
|
0.93i
|
5 (55.6)
|
11 (64.7)
|
0.69
|
|
Elevated moodc, n (%)
|
2 (11.1)
|
7 (17.1)
|
0.71
| | | | | | |
|
Irritabilityd, n (%)
|
3 (15.0)
|
6 (14.3)
|
1.00
|
3 (23.1)
|
5 (18.5)
|
1.00
|
1 (12.5)
|
5 (27.8)
|
0.63
|
|
Disorientatione, n (%)
|
1 (5.0)
|
7 (16.7)
|
0.26
|
4 (30.8)
|
4 (15.4)
|
0.40
|
0 (0)
|
2 (11.1)
|
1.00
|
|
Disinhibition (median (range))
|
1 (1–6)
|
1 (1–6)
|
0.57j
| | | | | | |
|
Agitation (median (range))f
|
8 (5–31)
|
8 (5–32)
|
0.62j
|
7 (5–27)
|
10 (5–21)
|
0.34j
|
10 (5–17)
|
8 (5–23)
|
0.98j
|
|
Symptom fluctuation (median (range))g
|
2 (1–7)
|
3 (1–8)
|
0.89j
| | | | | | |
|
Total sleep time (min) (mean (SD))h
|
458 (115)
|
476 (112)
|
0.66k
|
438 (109)
|
442 (114)
|
0.93k
| | | |
|
Time awake after sleep onset (min) (mean (SD))h
|
39 (23)
|
37 (35)
|
0.90k
|
47 (18)
|
40 (24)
|
0.51k
| | | |
- CASPR2 contactin-associated protein 2, GAD65 glutamic acid decarboxylase 65, NMDAR N-methyl-d-aspartate receptor, SD standard deviation
- aFisher’s exact test if not stated otherwise. Data missing on bNMDAR (3 cases, 1 control), CASPR2 (1 case, 3 controls), GAD65 (1 control); cNMDAR (3 cases, 1 control); dNMDAR (1 case), CASPR2 (1 case, 1 control), GAD65 (1 case); eNMDAR (1 case), CASPR2 (1 case, 2 controls), GAD65 (1 case); fCASPR2 (1 case, 1 control); gNMDAR (3 cases, 7 controls); hNMDAR (10 cases, 16 controls), CASPR2 (6 cases, 14 controls); iChi square; jMann Whitney U test; kT-test
